Table 2 Multivariate Cox regression model of retention in treatment by sex, age, region and substitution medications
From: Retention in the Austrian opioid agonist treatment system: a national prospective cohort study
| Variables | B | SE | Wald | df | Significance | Exp(B) | 95% CI Exp(B) |
|---|---|---|---|---|---|---|---|
| Sex (male) | − .216 | .061 | 12.443 | 1 | .000 | .806 | 0.714–0.908 |
| Age (older than 30) | .144 | .052 | 7.799 | 1 | .005 | 1.155 | 1.044–1.279 |
| Region (Vienna) | .364 | .062 | 33.918 | 1 | .000 | 1.439 | 1.273–1.626 |
| Buprenorphine | .332 | .068 | 24.190 | 1 | .000 | 1.394 | 1.221–1.591 |
| Buprenorphine/naloxone | − .037 | .105 | .126 | 1 | .723 | .964 | 0.785–1.183 |
| Slow-release morphine | .761 | .065 | 137.959 | 1 | .000 | 2.141 | 1.885–2.430 |
| Levo-methadone | .339 | .095 | 12.629 | 1 | .000 | 1.404 | 1.164–1.693 |